{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:49:33Z","timestamp":1792097373405,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jcf.2026.10.003","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:42:29Z","timestamp":1792096949000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Model-informed dose reduction of elexacaftor\/tezacaftor\/ivacaftor therapy in adult people with cystic fibrosis: A simulation study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-0901","authenticated-orcid":false,"given":"Tom C","family":"Zwart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3391-5356","authenticated-orcid":false,"given":"Syendon BC","family":"Baromeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inez","family":"Bronsveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-2843","authenticated-orcid":false,"given":"Harry GM","family":"Heijerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-7794","authenticated-orcid":false,"given":"Erik B","family":"Wilms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1818-6360","authenticated-orcid":false,"given":"Renske","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3\u20134","key":"10.1016\/j.jcf.2026.10.003_bib0001","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2298\/SARH1204244R","article-title":"Cystic fibrosis","volume":"140","author":"Radlovi\u0107","year":"2012","journal-title":"Srp Arh Celok Lek"},{"key":"10.1016\/j.jcf.2026.10.003_bib0002","first-page":"1662","article-title":"The changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Modulators","year":"2019","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jcf.2026.10.003_bib0003","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","volume":"10","author":"Mall","year":"2024","journal-title":"Cystic fibrosis. Nat Rev Dis Primers."},{"key":"10.1016\/j.jcf.2026.10.003_bib0004","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","article-title":"Cystic fibrosis modulator therapies","volume":"74","author":"Jia","year":"2023","journal-title":"Annu Rev Med"},{"issue":"10212","key":"10.1016\/j.jcf.2026.10.003_bib0005","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2026.10.003_bib0006","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcf.2026.10.003_bib0007","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/ppul.26412","article-title":"Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"58","author":"Baroud","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2026.10.003_bib0008","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2026.10.003_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1156621","article-title":"Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: a case series","volume":"14","author":"Ibrahim","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2026.10.003_bib0010","unstructured":"U.S. Food and Drug Administration. Center for drug evaluation and research. clinical pharmacology and biopharmaceutics review(s), Elexacaftor\/Tezacaftor\/Ivacaftor. 2019."},{"issue":"1","key":"10.1016\/j.jcf.2026.10.003_bib0011","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/FTD.0000000000001408","article-title":"Therapeutic drug monitoring of Elexacaftor, Tezacaftor, and Ivacaftor: an overview of bioanalytical methods","volume":"48","author":"Cafaro","year":"2026","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jcf.2026.10.003_bib0012","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1002\/bcp.70620","article-title":"Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis","volume":"92","author":"Magnas","year":"2026","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jcf.2026.10.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.70225","article-title":"Physiologically based pharmacokinetic modeling of Elexacaftor\/Tezacaftor\/Ivacaftor in infants with cystic fibrosis","volume":"15","author":"Truong","year":"2026","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.jcf.2026.10.003_bib0014","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jcf.2025.03.008","article-title":"Real-world pharmacokinetics of elexacaftor-tezacaftor-ivacaftor in children with cystic fibrosis: a prospective observational study","volume":"24","author":"Vonk","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2026.10.003_bib0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/phar.2786","article-title":"Safety of elexacaftor\/tezacaftor\/ivacaftor dose reduction: mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcf.2026.10.003_bib0016","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jcf.2024.03.010","article-title":"Amsterdam mucociliary clearance disease research G. correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor","volume":"23","author":"Vonk","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcf.2026.10.003_bib0017","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/jpm14101065","article-title":"Therapeutic drug monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in adult people with cystic fibrosis","volume":"14","author":"Naehrig","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.jcf.2026.10.003_bib0018","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jcf.2025.02.013","article-title":"Adverse events to elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis due to elevated drug exposure?: a case series","volume":"24","author":"Baromeo","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.10.003_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.actpsy.2026.106210","article-title":"Divergent neurobehavioral effects of CFTR modulators elexacaftor and ivacaftor in mice","volume":"263","author":"Ge","year":"2026","journal-title":"Acta Psychol (Amst)"},{"issue":"1","key":"10.1016\/j.jcf.2026.10.003_bib0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jcf.2024.09.010","article-title":"Regulatory adverse drug reaction analyses support a temporal increase in psychiatric reactions after initiation of cystic fibrosis combination modulator therapies","volume":"24","author":"O'Connor","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.10.003_bib0021","article-title":"Real-world safety profile of elexacaftor\/tezacaftor\/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system","volume":"16","author":"Zhu","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2026.10.003_bib0022","unstructured":"Foundation DCF. Dutch Cystic Fibrosis Foundation. 2025."},{"issue":"6","key":"10.1016\/j.jcf.2026.10.003_bib0023","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40262-025-01516-1","article-title":"Population pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a real-world cohort of adults with cystic fibrosis","volume":"64","author":"Magnas","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jcf.2026.10.003_bib0024","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and Research. clinical Pharmacology and Biopharmaceutics review(s), Tezacaftor\/Ivacaftor. 2017. Contract No.: Reference ID: 4216031."},{"key":"10.1016\/j.jcf.2026.10.003_bib0025","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and research. clinical pharmacology and biopharmaceutics review(s), Ivacaftor. 2012. Contract No.: Reference ID: 3073697."},{"issue":"9","key":"10.1016\/j.jcf.2026.10.003_bib0026","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/psp4.12445","article-title":"Nonlinear mixed-effects model development and simulation using nlmixr and related R open-source packages","volume":"8","author":"Fidler","year":"2019","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"12","key":"10.1016\/j.jcf.2026.10.003_bib0027","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/psp4.12471","article-title":"Performance of the SAEM and FOCEI algorithms in the open-source, nonlinear mixed effect modeling tool nlmixr","volume":"8","author":"Schoemaker","year":"2019","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"10.1016\/j.jcf.2026.10.003_bib0028","article-title":"Simple, automatic noncompartmental analysis: the PKNCA R package","volume":"42","author":"Denney","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"10.1016\/j.jcf.2026.10.003_bib0029","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s41030-020-00128-3","article-title":"Correction to: physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"6","author":"Tsai","year":"2020","journal-title":"Pulm Ther"},{"issue":"6","key":"10.1016\/j.jcf.2026.10.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01594-2025","article-title":"Impact of CFTR modulator concentrations on clinical response in cystic fibrosis","volume":"67","author":"Chalamalla","year":"2026","journal-title":"Eur Respir J"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326037732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326037732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:42:32Z","timestamp":1792096952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326037732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"alternative-id":["S1569199326037732"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.10.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Model-informed dose reduction of elexacaftor\/tezacaftor\/ivacaftor therapy in adult people with cystic fibrosis: A simulation study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}